GlassScriptPhysician profile
Karmen Penrose
NPI 1972268506
$766.31
in general payments reported to CMS, 2019-2025
16 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $126 · 2024: $174 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $75.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $115.99 | 2025 | Auvelity |
| Radius Health, INC. | $115.37 | 2025 | Tymlos |
| Sumitomo Pharma America, INC. | $99.09 | 2024-2025 | Gemtesa |
| Corcept Therapeutics | $75.07 | 2025 | Korlym |
| Mylan Specialty L.P. | $63.97 | 2023 | Yupelri |
| Amgen INC. | $61.74 | 2023 | Otezla |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $41.33 | 2024 | |
| Novo Nordisk INC | $37.44 | 2024 | Wegovy |
| C. R. Bard, INC. & Subsidiaries | $28.81 | 2025 | Bard Urinary Drainage Bag |
| Coloplast Corp | $22.40 | 2025 | |
| Astellas Pharma US INC | $20.23 | 2024 | Xtandi |
| Calyxo, INC. | $20.15 | 2025 | Cvac Aspiration System |
| Laborie Medical Technologies Corp. | $19.72 | 2025 | |
| Boston Scientific Corporation | $16.23 | 2025 | Axonics |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.03 | 2025 | Caplyta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $13.74 | 2025 | Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karmen Penrose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.